INTERVENTION 1:	Intervention	0
Experimental	Intervention	1
cyclophosphamide: chemotherapy	Intervention	2
cyclophosphamide	CHEBI:4026	0-16
doxorubicin hydrochloride: chemotherapy	Intervention	3
doxorubicin hydrochloride	CHEBI:31522	0-25
adjuvant therapy: chemotherapy	Intervention	4
adjuvant	CHEBI:60809	0-8
radiation therapy: chemotherapy	Intervention	5
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed adenocarcinoma of the breast by routine hematoxylin and eosin (H&E) staining	Eligibility	1
adenocarcinoma	DOID:299	25-39
breast	UBERON:0000310	47-53
Primary tumor  4 cm and 0-3 positive axillary lymph nodes (pathologic T1-2, pathologic N0-N1, M0)	Eligibility	2
lymph	UBERON:0002391	46-51
Patients with lymph nodes positive only by cytokeratin staining (i.e., H&E negative) are eligible	Eligibility	3
lymph	UBERON:0002391	14-19
No squamous cell carcinoma or sarcoma of the breast	Eligibility	4
squamous cell carcinoma	HP:0002860,DOID:1749	3-26
sarcoma	HP:0100242,DOID:1115	30-37
breast	UBERON:0000310	45-51
Patients must have undergone a segmental mastectomy (SM) with a level I and ll axillary dissection or sentinel lymph node biopsy within the past 14 weeks	Eligibility	5
lymph	UBERON:0002391	111-116
Surgical margins at the time of SM must be negative (> 3 mm) for both invasive carcinoma and for non-invasive ductal carcinoma	Eligibility	6
time	PATO:0000165	24-28
carcinoma	HP:0030731,DOID:305	79-88
carcinoma	HP:0030731,DOID:305	117-126
No active local-regional disease	Eligibility	7
active	PATO:0002354	3-9
disease	DOID:4,OGMS:0000031	25-32
Hormone receptor status not specified	Eligibility	8
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	9
patient	HADO:0000008,OAE:0001817	0-7
ECOG performance status 0-1	Eligibility	10
Sex: female	Eligibility	11
female	PATO:0000383	5-11
Menopausal status not specified	Eligibility	12
Not pregnant	Eligibility	13
Negative pregnancy test	Eligibility	14
Fertile patients must use effective non-hormonal contraception	Eligibility	15
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	Eligibility	16
skin cancer	DOID:4159	98-109
carcinoma	HP:0030731,DOID:305	113-122
No other serious or poorly controlled medical or psychiatric condition that could be exacerbated by, or complicate compliance with study treatment	Eligibility	17
condition	PDRO:0000129	61-70
PRIOR CONCURRENT THERAPY:	Eligibility	18
No prior radiation therapy to the breast	Eligibility	19
breast	UBERON:0000310	34-40
No prior trastuzumab (Herceptin Â®)	Eligibility	20
No other concurrent chemotherapy	Eligibility	21
No concurrent hormonal therapy except the following:	Eligibility	22
Steroids given for adrenal failure	Eligibility	23
Hormones administered for non-disease-related conditions (e.g., insulin for diabetes, synthroid for hypothyroidism)	Eligibility	24
insulin	CHEBI:145810	64-71
hypothyroidism	HP:0000821,DOID:1459	100-114
Intermittent dexamethasone as an antiemetic or premedication	Eligibility	25
dexamethasone	CHEBI:41879	13-26
antiemetic	CHEBI:50919	33-43
Outcome Measurement:	Results	0
Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity	Results	1
acute	HP:0011009,PATO:0000389	36-41
Number of participants with Grade 4 toxicity as defined by the following criteria:	Results	2
Acute Skin Toxicity: 0=No change, 1= Follicular, faint, or dull erythema/epilation/dry/desquamation/decreased swelling, 2= Tender or bright erythemal patchy moist desquamation/moderate edema, 3= Confluent moist desquamation other than skin folds, piting edema, 4= Ulceration, hemorrahage, necrosis, Late Skin Toxicity: 0= None, 1= Slight Atrophy, Pigmentation change, some hair loss, 2= Patch atrophy, moderate telangectasias, total hair loss, 3= Marked atrophy, gross telangectasias, 4= Ulceration; Subcutaneous Tissue Toxicity: 0= None, 1= Slight induration (fibrosis) and loss of subcutaneous fat, 2= Moderate fibrosis but asymptomatic; slight field contracture; <10% linear reduction, 3= Severe induration and loss subcutaneous tissue; field contracture >10% linear reduction; 4= Necrosis	Results	3
acute	HP:0011009,PATO:0000389	0-5
dull	HP:0025282	59-63
tender	HP:0025283	123-129
edema	HP:0000969	185-190
edema	HP:0000969	254-259
pigmentation	GO:0043473	347-359
moderate	HP:0012826	176-184
moderate	HP:0012826	402-410
moderate	HP:0012826	604-612
tissue	UBERON:0000479	513-519
tissue	UBERON:0000479	732-738
severe	HP:0012828	692-698
Time frame: up to 5 years	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Experimental	Results	6
Arm/Group Description: cyclophosphamide: chemotherapy	Results	7
cyclophosphamide	CHEBI:4026	23-39
doxorubicin hydrochloride: chemotherapy	Results	8
doxorubicin hydrochloride	CHEBI:31522	0-25
adjuvant therapy: chemotherapy	Results	9
adjuvant	CHEBI:60809	0-8
radiation therapy: chemotherapy	Results	10
Overall Number of Participants Analyzed: 25	Results	11
Measure Type: Count of Participants	Results	12
Unit of Measure: Participants  0   0.0%	Results	13
Adverse Events 1:	Adverse Events	0
Total: 1/25 (4.00%)	Adverse Events	1
Neutropenia *1/25 (4.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
